Skip to content

Study · Non-randomized trial · n = 20 · 1992

3 results

Cutaneous responses to vasoactive intestinal polypeptide in chronic idiopathic urticaria.

Smith CH, Atkinson B, Morris RW, Hayes N, Foreman JC, Lee TH

Lancet (London, England)1 Jan 1992Cited by 28 (Europe PMC)

PMID1370236 (opens in a new tab)DOI10.1016/0140-6736(92)91000-x (opens in a new tab)PepBankPUB-01370236
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In 10 patients with chronic idiopathic urticaria, VIP caused a significantly larger wheal than in 10 healthy controls.

    In plain wordsIn 10 patients with chronic hives, VIP caused a bigger skin wheal than in 10 healthy controls.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseVIP-induced cutaneous wheal
    Study

    n = 20

    Comparator
    Healthy controls
    Outcome group
    Skin reactions · Skin and wound
    Studied dose
    increasing concentrationsAs given in this study (human).

    Source sentences

    Summary
    A significant increase in VIP-induced wheal, but not flare or cutaneous blood flow, was seen in urticarial patients compared with controls (p less than 0.001)
    1 context sentence
    Summary · context
    Cutaneous wheal and flare responses to increasing concentrations of calcitonin gene-related peptide, substance P, neurokinin A, vasoactive intestinal polypeptide (VIP), compound 48/80, and phosphate-buffered saline were measured in 10 patients with chronic idiopathic urticaria and 10 healthy controls.
  2. 02HumanNon-randomized trialEfficacy outcome

    In 10 patients with chronic idiopathic urticaria, the VIP-induced flare did not differ significantly from 10 healthy controls.

    In plain wordsIn 10 patients with chronic hives, VIP caused no larger skin flare than in 10 healthy controls.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeVIP-induced cutaneous flare
    Study

    n = 20

    Comparator
    Healthy controls
    Outcome group
    Skin reactions · Skin and wound
    Studied dose
    increasing concentrationsAs given in this study (human).

    Source sentences

    Summary
    A significant increase in VIP-induced wheal, but not flare or cutaneous blood flow, was seen in urticarial patients compared with controls (p less than 0.001).
    1 context sentence
    Summary · context
    Cutaneous wheal and flare responses to increasing concentrations of calcitonin gene-related peptide, substance P, neurokinin A, vasoactive intestinal polypeptide (VIP), compound 48/80, and phosphate-buffered saline were measured in 10 patients with chronic idiopathic urticaria and 10 healthy controls.
  3. 03HumanNon-randomized trialEfficacy outcome

    In 10 patients with chronic idiopathic urticaria, VIP-induced cutaneous blood flow did not differ significantly from 10 healthy controls.

    In plain wordsIn 10 patients with chronic hives, VIP changed skin blood flow no more than in 10 healthy controls.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeVIP-induced cutaneous blood flow
    Study

    n = 20

    Comparator
    Healthy controls
    Outcome group
    Skin reactions · Skin and wound
    Studied dose
    increasing concentrationsAs given in this study (human).

    Source sentences

    Summary
    A significant increase in VIP-induced wheal, but not flare or cutaneous blood flow, was seen in urticarial patients compared with controls (p less than 0.001).
    1 context sentence
    Summary · context
    Cutaneous wheal and flare responses to increasing concentrations of calcitonin gene-related peptide, substance P, neurokinin A, vasoactive intestinal polypeptide (VIP), compound 48/80, and phosphate-buffered saline were measured in 10 patients with chronic idiopathic urticaria and 10 healthy controls.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.